Core Viewpoint - The Henan Provincial Government has issued an action plan to accelerate the integration of artificial intelligence in the modern pharmaceutical industry from 2025 to 2027, focusing on enhancing drug research and production efficiency through AI applications [1] Group 1: AI Applications in Pharmaceutical Industry - The plan emphasizes the application of large models in drug intelligent screening, clinical trial design and analysis, and optimization of drug synthesis processes to improve drug R&D efficiency and quality management [1] - It aims to break down barriers between biological data and healthcare data, strengthening the construction and training of traditional Chinese medicine large models to tackle the consistency issues of traditional Chinese medicine products [1] Group 2: AI in Medical Devices - The action plan also promotes the application of AI technology in auxiliary diagnostic testing, brain-machine interfaces, and intelligent rehabilitation for limbs, aiming to enhance the specificity and sensitivity of medical devices [1]

Core Insights - The Chinese Academy of Traditional Chinese Medicine has released evaluation standards for large models in traditional Chinese medicine, marking a significant development in the field [1] Group 1: Evaluation Standards - The newly established standards focus on the quantitative assessment of large models in the traditional Chinese medicine sector [1] - The evaluation framework emphasizes two main aspects: technical capabilities and application abilities [1] - The standards cover three major capability domains: scene richness, capability support, and application maturity, along with 13 sub-domains and over 30 capability items [1] Group 2: Application Focus - The three capability domains primarily address the breadth of application scenarios for large models in traditional Chinese medicine, the comprehensive technical capabilities throughout the process, and the service quality and effectiveness in practical applications [1]